Search

Displaying results 6331 - 6340 of 10000 in total
  1. Drug

    Utidelone

    go.drugbank.com/drugs/DB17575
    Investigational

    Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering.[A257544,A257549] It is under investigation in clinical trials for various cancers.

  2. Drug

    Bisphosphocin Nu-3

    go.drugbank.com/drugs/DB16015
    Investigational

    Bisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).

  3. Drug

    Propanidid

    go.drugbank.com/drugs/DB13234
    Experimental

    An intravenous anesthetic that has been used for rapid induction of anesthesia and for maintenance of anesthesia of short duration. (From Martindale, The Extra Pharmacopoeia, 30th ed, p918)

  4. Drug

    OTL-203

    go.drugbank.com/drugs/DB18643
    Investigational

    OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.

    Synonyms: Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene
  5. Drug

    Faxeladol

    go.drugbank.com/drugs/DB20529
    Investigational

    Effect of Food on it). … Faxeladol is under investigation in clinical trial NCT03765801 (A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the

  6. Drug

    Deramciclane

    go.drugbank.com/drugs/DB06512
    Investigational

    Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target.

  7. Drug

    ACY001

    go.drugbank.com/drugs/DB06355
    Experimental

  8. Drug

    AV-412

    go.drugbank.com/drugs/DB06021
    Investigational

  9. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  10. Drug

    ETC-1001

    go.drugbank.com/drugs/DB05866
    Experimental

    ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.